stoxline Quote Chart Rank Option Currency Glossary
  
Finch Therapeutics Group, Inc. (FNCH)
15  -0.5 (-3.23%)    02-14 13:33
Open: 15.5
High: 15.6
Volume: 2,292
  
Pre. Close: 15.5
Low: 15
Market Cap: 24(M)
Technical analysis
2025-02-14 4:48:09 PM
Short term     
Mid term     
Targets 6-month :  18.33 1-year :  21.41
Resists First :  15.69 Second :  18.33
Pivot price 12.77
Supports First :  12.73 Second :  10.89
MAs MA(5) :  15.34 MA(20) :  12.32
MA(100) :  11.68 MA(250) :  7.04
MACD MACD :  1 Signal :  0.6
%K %D K(14,3) :  91.9 D(3) :  94
RSI RSI(14): 79.3
52-week High :  15.69 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ FNCH ] has closed below upper band by 19.7%. Bollinger Bands are 408.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.62 - 15.7 15.7 - 15.77
Low: 14.81 - 14.9 14.9 - 14.98
Close: 14.85 - 15.01 15.01 - 15.14
Company Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Headline News

Thu, 06 Feb 2025
Finch Therapeutics: Post-Trial Decision Can Potentially Drive Shares To Trade Higher - Seeking Alpha

Sat, 01 Feb 2025
5 Best Microbiome Companies (February 2025) - Securities.io

Mon, 21 Oct 2024
Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire

Fri, 09 Aug 2024
Finch wins US jury trial against Ferring over fecal-transplant patents - Reuters

Sat, 24 Feb 2024
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation - TipRanks

Wed, 19 Apr 2023
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% - Penny Stocks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 1 (M)
Held by Insiders 53.4 (%)
Held by Institutions 4.6 (%)
Shares Short 19 (K)
Shares Short P.Month 11 (K)
Stock Financials
EPS -8.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.85
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21.9 %
Return on Equity (ttm) -67.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -12.12
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -1.71
PEG Ratio 0
Price to Book value 1.69
Price to Sales 0
Price to Cash Flow -1.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android